← Back to Clinical Trials
Recruiting NCT07622095

NCT07622095 Validation of the French Version of the New Mobility Score (NMS)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07622095
Status Recruiting
Phase
Sponsor Hospices Civils de Lyon
Condition Hip Fractures
Study Type OBSERVATIONAL
Enrollment 100 participants
Start Date 2026-08-27
Primary Completion 2028-02

Eligibility & Interventions

Sex All sexes
Min Age 75 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Questionnaires

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 100 participants in total. It began in 2026-08-27 with a primary completion date of 2028-02.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The incidence of hip fractures in France is 50,000 cases per year among women and 16,000 among men, with a 1-year mortality rate of 20-24%. After a fracture, 10-30% of patients become functionally dependent. The increasing aging of the population and the rise in dependency are likely to worsen the situation of older patients in hospital settings. Several tools are available to assess functional independence, including the New Mobility Score (NMS), which evaluates mobility through three domains: mobility indoors, mobility outdoors, and shopping activities. The NMS has shown good performance in predicting patient mortality and functional recovery, and its use is recommended in clinical practice. However, the French version of the NMS has not yet been validated. The French validation of the NMS is important to facilitate its implementation in clinical practice and research, particularly because of its simplicity and the need for rapid assessment tools for healthcare professionals. A French version of the NMS has been translated, and the MOB-SCORE study aims to assess its reliability and validity among healthcare professionals caring for patients with hip fractures.

Eligibility Criteria

Inclusion Criteria: * Patients aged 75 years and older admitted to a hospital department following a hip fracture and treated surgically (osteosynthesis or arthroplasty). * Type of fracture: pertrochanteric fracture or femoral neck fracture. * Sufficient proficiency in French to complete the questionnaires. * Patients affiliated with a health insurance scheme. * No objection to participate from the patient or the caregiver in case of cognitive impairment. Exclusion Criteria: no exclusion criteria

Contact & Investigator

Central Contact

Olivia FEBVEY-COMBES, MD

✉ olivia.febvey-combes@chu-lyon.fr

📞 (0)4 72 11 51 62

Frequently Asked Questions

Who can join the NCT07622095 clinical trial?

This trial is open to participants of all sexes, aged 75 Years or older, studying Hip Fractures. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07622095 currently recruiting?

Yes, NCT07622095 is actively recruiting participants. Contact the research team at olivia.febvey-combes@chu-lyon.fr for enrollment information.

Where is the NCT07622095 trial being conducted?

This trial is being conducted at Lyon, France.

Who is sponsoring the NCT07622095 clinical trial?

NCT07622095 is sponsored by Hospices Civils de Lyon. The trial plans to enroll 100 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology